Blood Work Before and After Peptides: How to Actually Know If Yours Is Working

The single biggest mistake people make when starting peptides is skipping the baseline. Without labs from before you start, you have no honest way to tell whether a peptide is working, whether it's causing a silent problem, or whether you're feeling the placebo effect — which for subjective endpoints like energy and mood can run as high as 30–40% in clinical trials.

Three things baseline testing gives you that nothing else can.

It sets your signal-to-noise floor. A1c fluctuates 0.1–0.3% between readings even when nothing has changed. IGF-1 can swing 20% day-to-day. Without a baseline, you cannot distinguish a real effect from noise.

It catches silent side effects early. Some of the most consequential peptide-related problems are asymptomatic until they aren't. Elevated IGF-1 on growth hormone secretagogues doesn't feel like anything. Rising lipase on GLP-1 agonists doesn't hurt until it does. Subclinical hypothyroidism creeps up invisibly. Labs are the only way to catch any of it early.

It gives honest feedback to your future self. Six months from now you will want to decide whether to continue, stop, or change peptides. Subjective recall ('I think I feel better?') is notoriously unreliable. Numbers aren't.

The rest of the piece is a practical map — a universal baseline panel that applies to almost any peptide, peptide-class-specific tests, cadence guidance, and red flags. Nothing here is medical advice; peptide decisions should be made with a clinician who knows your personal history. But going in armed with the right list of tests makes that conversation meaningfully more productive.

Before starting any peptide — GLP-1, growth hormone secretagogue, regenerative, cognitive, cosmetic — run this panel. Almost every test here is standard, covered by most insurance, and available via direct-to-consumer services like Quest or Labcorp without a prescription in most US states.

For metabolic and organ function: a comprehensive metabolic panel (electrolytes, kidney function via creatinine and eGFR, liver enzymes — ALT, AST, alkaline phosphatase, bilirubin), fasting glucose and HbA1c, fasting insulin with HOMA-IR (calculated from fasting glucose × insulin / 405; the Matthews 1985 Diabetologia paper validated HOMA as a reliable proxy for insulin resistance from two fasting values, and it's still the most practical metric in 2026), and a lipid panel — total cholesterol, LDL, HDL, triglycerides, ideally with ApoB if you can get it.

For inflammation and general health: CBC with differential, high-sensitivity CRP (the JUPITER trial — Ridker et al., NEJM 2008 — established hs-CRP as a primary-prevention biomarker in its own right, independent of LDL), 25-hydroxy vitamin D, and ferritin / iron studies if fatigue is a concern.

For hormones: TSH with free T4 (reflex to free T3 if TSH is abnormal), morning total testosterone with SHBG and free testosterone (both sexes — women need lower baselines but the data is still useful), estradiol and progesterone in women timed to menstrual cycle if cycling, and IGF-1 even if you're not taking a growth hormone secretagogue — it's a useful aging baseline, and you'll want it if you ever consider one.

For body composition: weight, waist circumference, body-fat estimate from bioimpedance at minimum. If you're about to start anything that moves body composition (GLP-1 agonists, growth hormone peptides), get a DEXA scan. It's the single highest-leverage test, because it tells you what kind of weight you're losing or gaining.

The panel costs roughly $200–600 direct-to-consumer depending on what's included. Most insurance covers almost all of it if your clinician orders it for 'metabolic assessment' or similar.

Weight-loss peptides — semaglutide, tirzepatide, retatrutide — improve most metabolic labs within 8–12 weeks. The baseline panel above already covers the essentials, but three things deserve extra attention:

What should improve:

• HbA1c. STEP-1 (semaglutide, NEJM 2021) and SURMOUNT-1 (tirzepatide, NEJM 2022) both showed meaningful A1c reductions in trial participants. If your A1c doesn't drop after 12 weeks of adequate dosing and reasonable diet, something is off.
• Fasting glucose, fasting insulin, HOMA-IR. HOMA-IR reductions of 40–60% are common on tirzepatide.
• Lipids — triglycerides typically drop 20–30%, LDL modestly, HDL often rises.
• ALT — fatty liver regresses rapidly on GLP-1 therapy, and ALT drops are often dramatic. This is one of the quiet wins of the class.
• hs-CRP — whole-body inflammation marker usually falls alongside weight loss.

What to actively watch:

• Body composition on DEXA. Weight loss from GLP-1 agonists includes a lean-mass component — typically 20–40% of total weight lost. A pre-treatment DEXA plus a follow-up at 6 months is the only way to know if you're preserving muscle. Combined with resistance training and adequate protein, lean-mass loss can be minimized. Without monitoring, it's invisible.
• Amylase and lipase. Pancreatitis is a rare but serious class side effect. Routine monitoring isn't consensus, but many clinicians draw baseline and follow-up lipase, especially for patients with any abdominal symptoms.
• Gallbladder ultrasound if symptomatic. Cholelithiasis risk rises with rapid weight loss.
• Thyroid exam and TSH. The FDA boxed warning on medullary thyroid carcinoma (MTC) is based on rodent data; human calcitonin screening is not recommended as routine. But a clinical thyroid exam and baseline TSH cover the realistic concerns.

Re-check cadence: A1c, lipids, ALT, fasting glucose/insulin, CMP at baseline, 12 weeks, 6 months, then annually. DEXA at baseline and 6 months.

Sermorelin, CJC-1295, ipamorelin, tesamorelin, and MK-677 all aim to raise endogenous growth hormone and, downstream, IGF-1. One lab dominates monitoring:

IGF-1 — the single most important test. IGF-1 is the integrated daily output of the GH axis and the only realistic blood marker of chronic GH elevation (GH itself is pulsatile and unusable for outpatient monitoring). The Bidlingmaier et al. 2014 JCEM reference intervals remain the standard source for age- and sex-matched normal ranges. Target: stay within the upper half of the age-matched normal range. Pushing IGF-1 above the reference ceiling is the realistic mechanism by which these peptides cause problems (insulin resistance, soft-tissue overgrowth, theoretical oncogenic risk).

Fasting glucose and HOMA-IR. GH reliably worsens insulin sensitivity. This is the most predictable adverse effect of the class, and MK-677 in particular has well-documented glucose-raising effects in trials. Monitor fasting glucose, fasting insulin, and A1c every 6–8 weeks for the first six months.

Prolactin. Some secretagogues can mildly elevate prolactin. Worth a baseline, rarely a concern.

Cortisol (morning serum). Older-generation GHRH/ghrelin-mimetic peptides can transiently raise cortisol. Less of an issue with modern ipamorelin-class agents, but baseline and 12-week recheck is reasonable.

Body composition — DEXA. The whole point of this class is usually to shift body composition toward more lean mass and less fat. Without pre/post DEXA, you're guessing. For tesamorelin specifically, the Falutz et al. 2007 NEJM trial demonstrated that visceral adipose tissue reductions were measurable on CT imaging — DEXA with visceral-fat estimates is a reasonable outpatient proxy.

Sleep, grip strength, waist circumference — cheap, weekly markers that correlate with meaningful function.

Re-check cadence: IGF-1 at baseline, 6 weeks, 12 weeks, then quarterly. Glucose/insulin/A1c every 8 weeks for six months, then twice yearly. DEXA at baseline and 6 months.

BPC-157 and TB-500 are the hardest peptides to monitor objectively, because their claimed effects — tissue repair, tendon healing, gut lining restoration — don't map cleanly onto any standard blood test. This is also the category where the placebo effect is most dangerous. People feel 'better' on regenerative peptides for reasons that have nothing to do with the peptide, and without objective measures, there's no way to tell.

Validated symptom questionnaires are the backbone of honest monitoring here. WOMAC for knee/hip osteoarthritis, DASH for shoulder/arm, VISA-A for Achilles work. IBS-SSS or GSRS for gut-healing applications. Brief Pain Inventory for non-specific chronic pain. Administer at baseline and monthly.

Inflammatory markers help if the baseline is elevated. hs-CRP dropping from 5 to 1 mg/L over 3 months is meaningful; changes within the 0–1 mg/L range are noise. ESR is a slower-moving inflammation marker, cheap, complementary to hs-CRP. Fecal calprotectin is a much better readout than hs-CRP for bowel-specific healing.

Imaging before and after is the highest-value test for serious injuries. Musculoskeletal ultrasound is cheap, operator-dependent, and excellent for tendons and partial tears. MRI is the gold standard for cartilage, meniscus, and structural tendon lesions — expensive, but definitive. Use the same modality pre and post, ideally with the same radiologist or AI-measured tendon thickness, so you're comparing like with like.

Functional testing is genuinely cheap. A grip strength dynamometer runs about $30 and works for upper-body recovery. Single-leg hop distance or jump height covers lower-body rehab. Range of motion can be measured with a phone app.

The honest framing: if your baseline is elevated hs-CRP plus a measurable functional deficit plus abnormal imaging, you have three independent readouts to track. If your baseline is 'I feel achy sometimes,' you have no realistic way to verify a peptide is working beyond self-report. That isn't a reason to skip monitoring. It's a reason to set up measurable baselines before you start.

Thymosin alpha-1 and related thymic peptides are used for immune modulation, often alongside chronic infection management, immunosenescence concerns, or post-illness recovery. The immune system is one of the few areas where blood work maps reasonably well onto the therapeutic goal.

The core immune panel:

• CBC with differential — baseline counts of lymphocytes, neutrophils, monocytes. Absolute lymphocyte count is often low at baseline in patients who end up on thymic peptides.
• Lymphocyte subsets (flow cytometry) — CD3, CD4, CD8, CD19, NK cells, and especially the CD4:CD8 ratio. A CD4:CD8 ratio below ~1.0 is a validated marker of immunosenescence and is the cleanest readout of thymic-axis function. The Liu et al. 2020 Clinical Infectious Diseases paper on thymosin alpha-1 in severe COVID-19 showed that the survival benefit tracked restoration of lymphocyte counts and reversal of T-cell exhaustion — the same mechanism you'd want to see in outpatient use.
• Immunoglobulins (IgG, IgA, IgM) — baseline useful if recurrent infections are the concern.
• Quantitative natural killer cell activity — specialized test, not universally available but valuable for chronic viral or oncology-adjacent use.

Inflammatory context:

• hs-CRP, ESR, IL-6 (if available) — chronic inflammation and T-cell exhaustion travel together.

Clinical tracking:

• Days of illness per year, severity of seasonal infections, time to recovery — these are subjective but powerful when tracked consistently over 6–12 months.

Re-check cadence: CBC and inflammatory markers every 3 months, lymphocyte subsets every 6 months.

A realistic win on thymic peptides looks like: CD4:CD8 ratio rising from 0.8 → 1.3, absolute lymphocyte count up 30%, hs-CRP down from 4 → 1 mg/L, and fewer/shorter illnesses over a year. That's measurable. "I feel more resilient" is not.

For cognitive peptides (semax, selank, cerebrolysin) and sexual health peptides (PT-141, kisspeptin), blood work plays a supporting role at best. The primary endpoints are functional and psychological, not biochemical.

Neuropeptides (cognition, anxiety, mood):

• Validated questionnaires are the primary endpoint. PHQ-9 for depression, GAD-7 for anxiety, PSQI for sleep quality, Cambridge Brain Sciences or CNS-VS for objective cognition. Administer at baseline and every 4 weeks.
• Sleep tracking (Oura, Whoop, Apple Watch) — more signal than most blood tests for this class.
• Supporting blood panel: TSH and free T4 (rule out thyroid-driven cognitive slowing), 25-OH vitamin D, B12, folate, homocysteine, ferritin. These are the differential diagnoses that masquerade as 'my peptide isn't working.'
• hs-CRP and fasting glucose/insulin — inflammation and insulin resistance both degrade cognition; correcting them can look like a peptide win.

Sexual health peptides:

• Total and free testosterone, SHBG, LH, FSH, estradiol, prolactin. These aren't readouts of PT-141 function per se (PT-141 is a central melanocortin agonist, not a hormonal therapy) but they rule out competing causes of low libido or erectile dysfunction that a peptide won't fix.
• Blood pressure monitoring — PT-141 transiently raises BP. Home BP cuff readings before and 2–6 hours after dosing are worth tracking for the first month.
• Validated questionnaires — IIEF-5 (men, erectile function), FSFI (women, female sexual function), and for PT-141 specifically the FSDS-R (distress scale) since Vyleesi's Phase 3 co-primary endpoints were desire and distress.
• For kisspeptin and fertility applications, the full hypothalamic-pituitary-gonadal panel is standard of care when working with a reproductive endocrinologist.

Cosmetic peptides (GHK-Cu, argireline, copper peptides):

• Standardized photography — same lighting, angle, distance, time of day, neutral background. This is cheap, doable at home, and the single best outcome measure for topical peptides.
• Corneometry and TEWL (transepidermal water loss) at a dermatology clinic if you want quantitative skin barrier data.
• Blood work is irrelevant for this category.

The common thread across these three sub-categories: structured, repeatable subjective measures (questionnaires, photography, device-based sleep/HRV data) often beat blood work, because the target outcome isn't a serum value. Setting up a standardized PHQ-9 every month or a standardized photo every 4 weeks is more useful than chasing a biomarker that doesn't exist.

Over-testing is expensive and anxiety-inducing. Under-testing defeats the purpose of having a baseline. A reasonable default cadence:

Before starting (baseline): The full universal panel + peptide-class-specific additions. Ideally within 4 weeks of starting.

4–6 weeks in: Short-term response check. For GLP-1 agonists: fasting glucose, ALT, a symptom review. For growth hormone secretagogues: IGF-1 + fasting glucose. For thymic peptides: CBC with differential. Skip this for regenerative or cosmetic peptides — too early to show anything.

12 weeks in: Full restudy of the peptide-class-specific panel plus a re-done questionnaire or functional test. This is your first real read on whether the peptide is working for you.

6 months in: Universal panel + peptide-class-specific panel + DEXA (if body composition is relevant). The 6-month mark is where stable-state effects emerge and decisions about continuing, changing dose, or stopping should be made.

Annually thereafter: Universal panel, peptide-class-specific panel, and any imaging (DEXA, ultrasound, etc.) that formed part of your baseline.

One pragmatic rule: don't change more than one variable at a time. If you start a new peptide, don't also start a new diet or training program in the same week, or you will never know what caused the change. If you do stack interventions, be explicit with yourself that you're testing the combination, not the peptide.

Some symptoms warrant immediate testing or clinical evaluation regardless of where you are in the schedule. The common ones by peptide class:

GLP-1 / GIP / triple agonists:

• Severe abdominal pain radiating to the back, persistent vomiting → pancreatitis workup (lipase, amylase, CT if indicated).
• Right-upper-quadrant pain, especially after rapid weight loss → gallbladder ultrasound.
• Unexplained neck lump, hoarseness, or persistent swallowing difficulty → thyroid imaging and ENT evaluation.
• Severe hypoglycemia symptoms (especially if on concurrent insulin or sulfonylurea) → glucose check, medication review.

Growth hormone secretagogues:

• Visual field disturbances, persistent headaches → pituitary MRI (acromegalic concerns, though rare at typical outpatient doses).
• New carpal tunnel symptoms, jaw/hand swelling, coarsening features → IGF-1 level, oral glucose tolerance test with GH measurement, endocrinology referral.
• New-onset diabetes symptoms (polyuria, polydipsia) → fasting glucose, A1c.

Regenerative / BPC-157 / TB-500:

• Unexplained bleeding, bruising → CBC with platelets, PT/INR.
• Growing skin lesions — theoretical oncogenic concerns for TB-500-class peptides given thymosin-β4's pro-angiogenic mechanism.

Sexual health peptides:

• Persistent severe flushing, chest pain, or blood pressure >160/100 after PT-141 dosing → hold peptide, cardiac evaluation.
• Priapism (erection >4 hours) — medical emergency.

Any peptide:

• New rash, wheezing, angioedema → allergic reaction workup, consider tryptase.
• Injection site that becomes warm, red, and painful beyond 48 hours → infection evaluation.
• Unexplained fever, night sweats, or weight loss → full workup; don't attribute to the peptide without exclusion.

The right default on any of these is: hold the peptide, get the test, then decide.

The gap between knowing what tests to run and having the results in hand is where most people stall. Four realistic paths.

Your primary care physician is the cheapest route if your PCP is willing to order metabolic, hormonal, and inflammatory panels as part of an annual physical. Frame the conversation around cardiometabolic risk and general health monitoring. 'I'd like to optimize my lipids and insulin sensitivity, and I'd appreciate a baseline hormonal panel' lands very differently than 'I'm about to start a research peptide.' Most of the universal baseline fits cleanly under standard-of-care preventive labs and is covered by insurance.

Direct-to-consumer lab services are the second path. Quest's QuestDirect, Labcorp's OnDemand, Function Health, Marek Health, Inside Tracker, and similar services let you order most of the universal panel without a physician referral in the majority of US states. Cash prices run $200–600 for a comprehensive panel. IGF-1, lymphocyte subsets, and hs-CRP are all orderable. The downside is that you get the numbers but not a clinician to interpret them — worth pairing with a telehealth consult.

A peptide-literate clinician — concierge, functional medicine, longevity clinic, or telehealth peptide program — is increasingly the best-value option for serious users. These clinics order the full relevant panel, interpret results, and adjust dosing. Cost runs higher ($300–800/visit plus lab fees), but these clinicians actually know what IGF-1 targets look like on sermorelin or what DEXA trends are acceptable on tirzepatide.

Your specialist (endocrinologist, reproductive endocrinologist, gastroenterologist) covers FDA-approved peptide indications. If you're using semaglutide for obesity/diabetes, tesamorelin for HIV lipodystrophy, kisspeptin in a fertility clinic, or bremelanotide for HSDD, the specialist will generally run appropriate monitoring labs as part of routine care. Ask explicitly for a copy of every result — you want the longitudinal data in your own hands.

The portable-records rule applies regardless of who orders the labs. Get the actual numerical results exported to a single place you control. A shared Google Sheet or a health-tracking app that lets you import PDFs is enough. Trends over years are where the real signal lives, and that data disappears fast if it's scattered across four different patient portals.